mplementation of a Multimodal Machine Perfusion Program in Liver Transplantation: A Real-World Analysis of Clinical Outcomes, Logistics, and Resource Use in a European High-Volume Center

mplementation of a Multimodal Machine Perfusion Program in Liver Transplantation: A Real-World Analysis of Clinical Outcomes, Logistics, and Resource Use in a European High-Volume Center - MP IMPLEMENT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039800

Enrollment

100

Registered

2026-04-01

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K70 K71 K72 K73 K74 K75 K76 K77

Interventions

Group 1: Normothermic machine perfusion Group 2: Hypothermic machine perfusion Group 3: Static cold storage

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: all performed liver transplantations

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Occurrence of early allograft dysfunction (EAD) within the first 7 postoperative days after liver transplantation, defined as the presence of at least one of the following criteria: serum bilirubin = 10 mg/dL on postoperative day 7, INR = 1.6 on postoperative day 7, or ALT/AST > 2000 IU/L within the first 7 postoperative days. Assessment will be performed retrospectively using routine laboratory data documented in the hospital information system.	—

Measure

Time frame

Occurrence of early allograft dysfunction (EAD) within the first 7 postoperative days after liver transplantation, defined as the presence of at least one of the following criteria: serum bilirubin = 10 mg/dL on postoperative day 7, INR = 1.6 on postoperative day 7, or ALT/AST > 2000 IU/L within the first 7 postoperative days. Assessment will be performed retrospectively using routine laboratory data documented in the hospital information system.

—

Secondary

Measure	Time frame
Peak ALT and AST levels within the first 7 postoperative days Additional laboratory parameters: bilirubin, INR, platelet count, albumin, creatinine, urea, lactate, GFR, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) Primary non-function (PNF) Biliary complications Cellular rejection episodes Surgical complications within 30 days and at 3 and 12 months, assessed according to Clavien-Dindo classification and the Comprehensive Complication Index (CCI) Recipient survival Graft survival Correlation of intraoperative perfusion parameters with postoperative clinical endpoints Organ utilization rates Organ discard rates Total preservation time Length of intensive care unit stay Costs of intensive care unit stay Length of hospital stay Costs of hospital stay Impact on the accepted donor organ profile, including ET-DRI and ECD criteria Organ acceptance rate Waiting list mortality Mean waiting time before and after implementation of the machine perfusion (MP) program Extent of nighttime transplant activity	—

Measure

Time frame

Peak ALT and AST levels within the first 7 postoperative days Additional laboratory parameters: bilirubin, INR, platelet count, albumin, creatinine, urea, lactate, GFR, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) Primary non-function (PNF) Biliary complications Cellular rejection episodes Surgical complications within 30 days and at 3 and 12 months, assessed according to Clavien-Dindo classification and the Comprehensive Complication Index (CCI) Recipient survival Graft survival Correlation of intraoperative perfusion parameters with postoperative clinical endpoints Organ utilization rates Organ discard rates Total preservation time Length of intensive care unit stay Costs of intensive care unit stay Length of hospital stay Costs of hospital stay Impact on the accepted donor organ profile, including ET-DRI and ECD criteria Organ acceptance rate Waiting list mortality Mean waiting time before and after implementation of the machine perfusion (MP) program Extent of nighttime transplant activity

—

Countries

Germany

Contacts

Public ContactDeniz Uluk

Universitätsklinikum Heidelberg

doctordenizuluk@gmail.com00496221566201

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026